Valeant To Buy Bausch & Lomb For $8.7 Billion In Cash
This article was originally published in PharmAsia News
Executive Summary
Specialty pharmaceuticals maker Valeant Pharmaceuticals International announced it will buy Bausch & Lomb for $8.7 billion in cash with $4.5 billion paid to the Warburg Pincus-led investment group that owns Bausch.